Smoking and HIV: what are the risks and what harm reduction strategies do we have at our disposal? by Michelle L. Giles, Coral Gartner, Mark A. Boyd

Get full text

Preservation of Gastrointestinal Mucosal Barrier Function and Microbiome in Patients With Controlled HIV Infection by Gerald Mak, John J. Zaunders, Michelle Bailey, Nabila Seddiki, Geraint Rogers, Geraint Rogers, Lex Leong, Tri Giang Phan, Tri Giang Phan, Anthony D. Kelleher, Kersten K. Koelsch, Mark A. Boyd, Mark A. Boyd, Mark A. Boyd, Mark Danta, Mark Danta

Get full text

Exploring the readiness of senior doctors and nurses to assess and address patients’ social needs in the hospital setting by Katherine J. Lake, Mark A. Boyd, Lisa Smithers, Natasha J. Howard, Anna P. Dawson

Get full text

Correction to: Exploring the readiness of senior doctors and nurses to assess and address patients’ social needs in the hospital setting by Katherine J. Lake, Mark A. Boyd, Lisa Smithers, Natasha J. Howard, Anna P. Dawson

Get full text

Impact of health literacy and its interventions on health outcomes in those with atrial fibrillation: a systematic review protocol by Rajiv Mahajan, Mark A Boyd, Nathan O'Callaghan, Kyle B Franke, Timothy Lathlean, Don Kieu

Get full text

Preventing empirical antibiotic treatment failure in migrant populations: screening by infection risk, not ethnic background by Steven L. Taylor, Lito E. Papanicolas, Erin Flynn, Mark A. Boyd, Steve L. Wesselingh, Geraint B. Rogers

Get full text

Sociodemographic, lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population: an 18-year follow-up of the North West Adelaide Health Stu... by Catherine Hill, Yohannes Adama Melaku, Tiffany K Gill, Sarah L Appleton, Mark A Boyd, Robert J Adams

Get full text

Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial. by Amit C Achhra, Mark A Boyd, Matthew G Law, Gail V Matthews, Anthony D Kelleher, David A Cooper

Get full text

The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa. by Karen Schneider, Chidi Nwizu, Richard Kaplan, Jonathan Anderson, David P Wilson, Sean Emery, David A Cooper, Mark A Boyd

Get full text

Capturing the social determinants of health at the individual level: a pilot study by Kate E Neadley, Gai McMichael, Toby Freeman, Kathryn Browne-Yung, Fran Baum, Elaine Pretorius, Karen Taylor, Mark A Boyd

Get full text

Development of recommendations for a minimum dataset for Identifying Social factors that Stratify Health Opportunities and Outcomes (ISSHOOs) in pain research by Emma L. Karran, Aidan G. Cashin, Trevor Barker, Mark A. Boyd, Alessandro Chiarotto, Vina Mohabir, Jennifer Petkovic, Saurab Sharma, Peter Tugwell, G. Lorimer Moseley

Get full text

The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study by Swe Swe Thit, Ne Myo Aung, Zaw Win Htet, Mark A. Boyd, Htin Aung Saw, Nicholas M. Anstey, Tint Tint Kyi, David A. Cooper, Mar Mar Kyi, Josh Hanson

Get full text

HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-l... by Allison Martin, Cecilia L Moore, Patrick W G Mallon, Jennifer F Hoy, Sean Emery, Waldo H Belloso, Praphan Phanuphak, Samuel Ferret, David A Cooper, Mark A Boyd, Second-Line Study Team

Get full text

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis by Nathan W. Cummins, Jacqueline Neuhaus, Haitao Chu, James Neaton, Christoph Wyen, Jürgen K. Rockstroh, Daniel J. Skiest, Mark A. Boyd, Saye Khoo, Margalida Rotger, Amalio Telenti, Richard Weinshilboum, Andrew D. Badley

Get full text

Investigating potential transmission of antimicrobial resistance in an open-plan hospital ward: a cross-sectional metagenomic study of resistome dispersion in a lower middle-income... by Anushia Ashokan, Josh Hanson, Ne Myo Aung, Mar Mar Kyi, Steven L. Taylor, Jocelyn M. Choo, Erin Flynn, Fredrick Mobegi, Morgyn S. Warner, Steve L. Wesselingh, Mark A. Boyd, Geraint B. Rogers

Get full text

Exploring self-determined solutions to service and system challenges to promote social and emotional wellbeing in Aboriginal and Torres Strait Islander people: a qualitative study by Anna P. Dawson, Anna P. Dawson, Eugene Warrior, Odette Pearson, Odette Pearson, Mark A. Boyd, Mark A. Boyd, Judith Dwyer, Kim Morey, Tina Brodie, Kurt Towers, Sonia Waters, Cynthia Avila, Courtney Hammond, Katherine J. Lake, Katherine J. Lake, ‘Uncle’ Frank Lampard, ‘Uncle’ Frank Lampard, ‘Uncle’ Frank Wanganeen, Olive Bennell, Darrien Bromley, Toni Shearing, Nathan Rigney, Schania Czygan, Nikki Clinch, Andrea Pitson, Alex Brown, Alex Brown, Natasha J. Howard, Natasha J. Howard

Get full text

CD4+ T follicular helper and IgA+ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are comparable to HIV-uninfected individuals by John Zaunders, Mark Danta, Michelle Bailey, Gerald Mak, Katherine Marks, Nabila Seddiki, Yin Xu, David J Templeton, David J Templeton, David J Templeton, David A Cooper, Mark A Boyd, Anthony Dominic Kelleher, Kersten K Koelsch

Get full text

The ‘what’ and ‘how’ of screening for social needs in healthcare settings: a scoping review by Emma L. Karran, Aidan G. Cashin, Trevor Barker, Mark A. Boyd, Alessandro Chiarotto, Omar Dewidar, Jennifer Petkovic, Saurab Sharma, Peter Tugwell, G. Lorimer Moseley, Identifying Social Factors that Stratify Health Opportunities and Outcomes (ISSHOOs) Collaborative Core Research Group

Get full text

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infect... by Janaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, Cecilia L Moore, Marcello H Losso, Chidi A Nwizu, Lerato Mohapi, Stephen J Kerr, Annette H Sohn, Hedy Teppler, Boris Renjifo, Jean-Michel Molina, Sean Emery, David A Cooper

Get full text

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of... by Janaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, Cecilia L Moore, Marcello H Losso, Chidi A Nwizu, Lerato Mohapi, Stephen J Kerr, Annette H Sohn, Hedy Teppler, Boris Renjifo, Jean-Michel Molina, Sean Emery, David A Cooper, SECOND-LINE

Get full text